| | |
Bloomberg 11:06 PM | November 20,2009
Gurgaon-based Ranbaxy voluntarily recalled 40 mg capsules of isotretinoin, the chemical ingredient in Accutane, the company said in a statement on Friday
|
|
Radhieka Pandeya 09:12 PM | October 26,2009
The company has registered a profit despite a 53% decline in sales in the US and a 25% drop in Romania
|
|
C.H. Unnikrishnan 10:28 PM | August 24,2009
The company is also in talks with a clutch of research-based drug companies in India to license potential technologies for products that can compensate it for the lost market slot
|
|
Radhieka Pandeya 12:30 AM | August 19,2009
Lupin currently has at least 200 products in Japanese market and extensive operations in Africa as well
|
|
Radhieka Pandeya 11:19 PM | August 07,2009
Zenotech and Daiichi have been at loggerheads since Daiichi acquired Ranbaxy Laboratories Ltd, over the price of the open offer shares
|
|
Radhieka Pandeya 12:02 AM | August 01,2009
It includes Ranbaxy results after a 3-month lag; Q1 doesn’t reflect gains made by Indian drug maker in Apr-Jun
|
|
Reuters 09:31 AM | July 15,2009
Zenotech’s minority shareholders complained to the Madras high court that Daiichi Sankyo’s offer to pay Rs113.62 per share was too low and that they would seek Rs160 per share
|
|
PTI 04:00 PM | July 09,2009
The company clarified that this is a class III recall, which signifies that the use or exposure to the product is not likely to cause adverse effects
|
|
Radhieka Pandeya 10:20 PM | May 13,2009
Japanese company will have to strengthen its involvement in the management of the Indian firm, says CEO
|
|
C.H. Unnikrishnan 10:42 PM | April 29,2009
Sales of Rabipur for the year ended 31 December 2008 were Rs117.94 crore
|
|
PTI 04:42 PM | March 25,2009
With the approval of this drug, Ranbaxy now has a total number of 27 molecules approved for marketing in Australia
|
|
Reuters and PTI 10:46 PM | March 06,2009
With the approval of this tablet, Ranbaxy now has a total number of 26 molecules approved for marketing in Australia
|
|
Radhieka Pandeya 01:15 AM | March 06,2009
The USFDA said on 25 February that Ranbaxy won’t be allowed to introduce new generic drugs from the Paonta Sahib plant because it falsified data about products’ shelf life
|
|
Radhieka Pandeya and C.H. Unnikrishnan 12:22 AM | February 28,2009
India’s drug industry is concerned this could mean slower drug approvals for other pharma companies
|
|
C.H. Unnikrishnan and Ashwin Ramarathinam 12:09 AM | February 09,2009
It has been the worst performance in 12 quarters mainly due to currency fluctuations and weak capital market
|
|